Press Release Details

Corporate
Henry Schein at a Glance

Press Release Details

Henry Schein Reports Record Third Quarter Results

11/04/09
Net sales up 6.9% in local currencies excluding seasonal influenza vaccines

MELVILLE, N.Y., Nov. 4 /PRNewswire-FirstCall/ -- Henry Schein, Inc. (Nasdaq: HSIC), the largest provider of healthcare products and services to office-based practitioners, today reported record financial results for the quarter ended September 26, 2009.

Net sales for the third quarter of 2009 were $1.7 billion, an increase of 0.9% compared with the third quarter of 2008. This consists of a 3.1% decline related to foreign currency exchange and a 4.0% growth in local currencies. Excluding sales of seasonal influenza vaccines, which declined from last year's third quarter, net sales increased 3.7%, or 6.9% growth in local currencies (see Exhibit A for details of sales growth).

Income from continuing operations attributable to Henry Schein, Inc. for the third quarter of 2009 was $94.0 million or $1.03 per diluted share, an increase of 39.2% for both figures compared with the third quarter of 2008. Current and prior-year results include certain unusual items, most notably an overseas tax benefit in the 2009 quarter. Excluding these items, non-GAAP income from continuing operations was $72.9 million or $0.80 per share, an increase of 3.3% and 3.9%, respectively, compared with the third quarter of 2008 (see Exhibit B for reconciliation of GAAP income and EPS from continuing operations to non-GAAP income and EPS from continuing operations). When also excluding sales of seasonal influenza vaccines, which declined from last year's third quarter, non-GAAP diluted EPS from continuing operations increased approximately 18%.

"We are pleased to report net sales growth in local currencies of approximately 7% excluding sales of seasonal influenza vaccines, with solid increases in our Medical, International and Technology Groups," said Stanley M. Bergman, Chairman and Chief Executive Officer of Henry Schein. "A number of unusual items impacted our third quarter results in both the current and prior year. On a normalized basis excluding these items and sales of seasonal influenza vaccines, we are proud to report 18% growth in diluted EPS from continuing operations."

Dental Group sales of $622 million declined 3.0%, consisting of a 0.5% decline related to foreign currency exchange and a 2.5% decline in local currencies. The 2.5% decline in local currencies included 1.3% growth in Dental consumable merchandise sales and a 12.8% decline in Dental equipment sales and service revenues.

"We continue to believe that the market for Dental consumable merchandise has stabilized and, as expected, our decrease in sales of Dental equipment has improved from the previous quarter's rate of decline," commented Mr. Bergman.

Medical Group sales of $411 million declined 3.1%. Excluding sales of seasonal influenza vaccines, Medical Group sales increased 8.6%.

"During the third quarter we sold approximately 6.5 million doses of seasonal influenza vaccine, and as of today we have sold approximately 8.5 million doses for the year," said Mr. Bergman. "Sales growth of nearly 9% excluding seasonal influenza vaccine reflects strong sales of consumable products, as well as sales of products related to the treatment and prevention of the H1N1 virus."

International Group sales of $584 million increased 8.5%, consisting of an 8.4% decline related to foreign currency exchange and 16.9% growth in local currencies.

"We had double-digit local currency sales growth in our International dental, medical and veterinary businesses during the quarter," added Mr. Bergman.

Technology and Value-Added Services Group sales of $43 million increased 5.4% during the quarter, consisting of a 1.9% decline related to foreign currency exchange and 7.3% growth in local currencies.

"During the quarter we saw continued strong growth in electronic services, as well as the beneficial impact of the acquisition of a European veterinary software and practice management business," explained Mr. Bergman.

Year-to-Date Results

For the first nine months of 2009, net sales of $4.8 billion represent a decrease of 1.0% compared with the first nine months of 2008. This decrease includes a 5.9% decline related to foreign currency exchange and 4.9% growth in local currencies.

Income from continuing operations attributable to Henry Schein, Inc. for the first nine months of 2009 was $222.1 million or $2.45 per diluted share, an increase of 20.6% and 22.5%, respectively, compared with the first nine months of 2008. Excluding unusual items noted above, income from continuing operations attributable to Henry Schein, Inc. for the first nine months of 2009 was $203.8 million or $2.25 per diluted share, an increase of 8.8% and 10.3%, respectively, compared with the first nine months of 2008 (see Exhibit B for reconciliation of GAAP income and EPS from continuing operations to non-GAAP income and EPS from continuing operations).

2009 EPS Guidance

Henry Schein today updated 2009 financial guidance, as follows:

    --  Fourth quarter 2009 diluted EPS attributable to Henry Schein, Inc. is
        expected to be $0.89 to $0.91.
    --  2009 diluted EPS attributable to Henry Schein, Inc. is expected to be
        $3.14 to $3.16 excluding the unusual items included in Exhibit B.  This
        represents growth of approximately 8% compared with restated 2008
        results of $2.92, excluding charges related to the Lehman Brothers
        bankruptcy as well as restructuring costs.

    --  Guidance for 2009 diluted EPS attributable to Henry Schein, Inc. is for
        current continuing operations including completed or previously
        announced acquisitions, and does not include the impact of potential
        future acquisitions, if any.

2010 EPS Guidance

Henry Schein today introduced 2010 financial guidance, as follows:

    --  2010 diluted EPS attributable to Henry Schein, Inc. is expected to be
        $3.40 to $3.56, representing growth of 8% to 13% compared with the
        midpoint of 2009 guidance.

    --  Guidance for 2010 diluted EPS attributable to Henry Schein, Inc. is for
        current continuing operations including completed or previously
        announced acquisitions, and does not include the impact of potential
        future acquisitions, if any.

Third Quarter Conference Call Webcast

The Company will hold a conference call to discuss third quarter financial results today, beginning at 10:00 a.m. Eastern time. Individual investors are invited to listen to the conference call over the Internet through Henry Schein's Web site at www.henryschein.com. In addition, a replay will be available beginning shortly after the call has ended.

About Henry Schein

Henry Schein, a Fortune 500® company and a member of the NASDAQ 100® Index, is recognized for its excellent customer service and highly competitive prices. The Company's four business groups - Dental, Medical, International and Technology - serve more than 575,000 customers worldwide, including dental practitioners and laboratories, physician practices and animal health clinics, as well as government and other institutions. The Company operates through a centralized and automated distribution network, which provides customers in more than 200 countries with a comprehensive selection of more than 90,000 national and Henry Schein private-brand products in stock, as well as more than 100,000 additional products available as special-order items. Henry Schein also provides exclusive, innovative technology offerings for dental, medical and veterinary professionals, including value-added practice management software and electronic health record solutions.

Headquartered in Melville, N.Y., Henry Schein employs over 12,500 people and has operations or affiliates in 23 countries. The Company's net sales reached a record $6.4 billion in 2008. For more information, visit the Henry Schein Web site at www.henryschein.com.

In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements are identified by the use of such terms as "may," "could," "expect," "intend," "believe," "plan," "estimate," "forecast," "project," "anticipate" or other comparable terms. A full discussion of our operations and financial condition, including factors that may affect our business and future prospects, is contained in documents we have filed with the SEC and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations.

Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: decreased customer demand and changes in vendor credit terms; disruptions in financial markets; general economic conditions; competitive factors; changes in the healthcare industry; changes in regulatory requirements that affect us; risks associated with our international operations; fluctuations in quarterly earnings; our dependence on third parties for the manufacture and supply of our products; transitional challenges associated with acquisitions, including the failure to achieve anticipated synergies; financial risks associated with acquisitions; regulatory and litigation risks; the dependence on our continued product development, technical support and successful marketing in the technology segment; our dependence upon sales personnel and key customers; our dependence on our senior management; possible increases in the cost of shipping our products or other service issues with our third-party shippers; risks from rapid technological change; risks from potential increases in variable interest rates; possible volatility of the market price of our common stock; certain provisions in our governing documents that may discourage third-party acquisitions of us; and changes in tax legislation that affect us. The order in which these factors appear should not be construed to indicate their relative importance or priority.

We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements.


                              (TABLES TO FOLLOW)



                               HENRY SCHEIN, INC.
                         CONSOLIDATED STATEMENTS OF INCOME
                       (in thousands, except per share data)
                                    (unaudited)

                         Three Months Ended             Nine Months Ended
                         ------------------             -----------------
                   September 26,  September 27,   September 26,  September 27,
                       2009           2008            2009           2008
                       ----           ----            ----           ----

    Net sales       $1,659,433    $1,644,209      $4,752,255     $4,799,234
    Cost of sales    1,183,166     1,168,615       3,361,707      3,389,847
                     ---------     ---------       ---------      ---------
      Gross profit     476,267       475,594       1,390,548      1,409,387
    Operating
     expenses:
      Selling,
       general and
       administrative  362,382       360,180       1,060,062      1,094,512
      Restructuring
       costs                 -             -           4,043              -
                           ---           ---           -----            ---
        Operating
         income        113,885       115,414         326,443        314,875
    Other income
     (expense):
      Interest income    2,387         4,260           7,674         12,217
      Interest expense  (5,171)       (9,240)        (18,329)       (26,816)
      Other, net         1,938        (4,863)          1,595         (5,524)
                         -----        ------           -----         ------
       Income from
        continuing
        operations
        before taxes,
        equity in
        earnings of
        affiliates and
        noncontrolling
        interests      113,039       105,571         317,383        294,752
    Income taxes       (15,864)      (34,355)        (83,402)       (98,787)
    Equity in earnings
     of affiliates       1,200         1,602           3,777          4,020
                         -----         -----           -----          -----
    Income from
     continuing
     operations         98,375        72,818         237,758        199,985
       Income (loss)
        from
        discontinued
        operations,
        net of tax       2,373           (52)          2,715           (828)
                         -----           ---           -----           ----
    Net income         100,748        72,766         240,473        199,157
      Less: Net income
       attributable to
       noncontrolling
       interests        (4,327)       (5,278)        (15,728)       (15,659)
                        ------        ------         -------        -------
    Net income
     attributable to
     Henry Schein,
     Inc.              $96,421       $67,488        $224,745       $183,498
                       =======       =======        ========       ========

    Amounts
     attributable to
     Henry Schein,
     Inc.:
      Income from
       continuing
       operations      $94,045        $67,548       $222,143       $184,239
      Income (loss)
       from
       discontinued
       operations,
       net of tax        2,376            (60)         2,602           (741)
                         -----            ---          -----           ----
      Net income       $96,421        $67,488       $224,745       $183,498
                       =======        =======       ========       ========

    Earnings per share
     attributable to
     Henry Schein, Inc.:

    From continuing
     operations:
        Basic            $1.06          $0.76          $2.50          $2.07
                         =====          =====          =====          =====
        Diluted          $1.03          $0.74          $2.45          $2.00
                         =====          =====          =====          =====

    From discontinued
     operations:
        Basic            $0.03          $0.00          $0.03         $(0.01)
                         =====          =====          =====         ======
        Diluted          $0.02          $0.00          $0.03          $0.00
                         =====          =====          =====          =====

    From net income:
        Basic            $1.09          $0.76          $2.53          $2.06
                         =====          =====          =====          =====
        Diluted          $1.05          $0.74          $2.48          $2.00
                         =====          =====          =====          =====

    Weighted-average
     common shares
     outstanding:
        Basic           88,796         88,930         88,843         89,216
                        ======         ======         ======         ======
        Diluted         91,513         91,376         90,576         91,908
                        ======         ======         ======         ======

    Note: The above prior period amounts have been restated to reflect the
    effects of discontinued operations, the adoption of ASC Topic 470-20
    related to convertible debt and ASC Topic 810-10-65 related to the
    presentation of noncontrolling interests.



                               HENRY SCHEIN, INC.
                          CONSOLIDATED BALANCE SHEETS
               (in thousands, except share and per share data)

                                      September 26,             December 27,
                                          2009                      2008
                                          ----                      ----
                                      (unaudited)
    ASSETS
    Current assets:
        Cash and cash equivalents      $317,607                  $369,570
        Accounts receivable,
         net of reserves of
         $47,890 and $42,855            764,285                   734,027
        Inventories, net                770,370                   731,654
        Deferred income taxes            40,747                    36,974
        Prepaid expenses and other      186,744                   193,841
                                        -------                   -------
          Total current assets        2,079,753                 2,066,066
    Property and equipment, net         257,602                   247,835
    Goodwill                            977,054                   922,952
    Other intangibles, net              212,042                   214,093
    Investments and other               176,888                   148,264
                                        -------                   -------
          Total assets               $3,703,339                $3,599,210
                                     ==========                ==========

    LIABILITIES AND
     STOCKHOLDERS' EQUITY
    Current liabilities:
        Accounts payable               $507,462                  $554,773
        Bank credit lines                 1,731                     4,936
        Current maturities of
         long-term debt                  23,933                   156,405
        Accrued expenses:
           Payroll and related          148,665                   135,523
           Taxes                         83,951                    69,792
           Other                        263,392                   262,236
                                        -------                   -------
          Total current
           liabilities                1,029,134                 1,183,665
    Long-term debt                      242,511                   256,648
    Deferred income taxes               107,953                    95,399
    Other liabilities                    72,038                    58,109

    Redeemable noncontrolling
     interests                          177,513                   233,035
    Commitments and contingencies

    Stockholders' equity:
       Preferred stock, $.01
        par value, 1,000,000
        shares authorized,
        none outstanding                      -                         -
       Common stock, $.01 par
        value, 240,000,000
        shares authorized,
        90,448,417
        outstanding on
        September 26, 2009
        and 89,351,849
        outstanding on
        December 27, 2008                   904                       894
       Additional paid-in
        capital                         533,508                   492,505
       Retained earnings              1,406,199                 1,181,454
       Accumulated other
        comprehensive income             71,863                    29,721
                                         ------                    ------
       Total Henry Schein, Inc.
        stockholders' equity          2,012,474                 1,704,574
       Noncontrolling interests          61,716                    67,780
                                         ------                    ------
          Total stockholders'
           equity                     2,074,190                 1,772,354
                                      ---------                 ---------
          Total liabilities and
           stockholders' equity      $3,703,339                $3,599,210
                                     ==========                ==========


    Note: The above prior period amounts have been restated to reflect the
    adoption of ASC Topic 480-10 related to redeemable noncontrolling
    interests, ASC Topic 470-20 related to convertible debt and ASC Topic
    810-10-65 related to the presentation of noncontrolling interests.



                                HENRY SCHEIN, INC.
                       CONSOLIDATED STATEMENTS OF CASH FLOWS
                                  (in thousands)
                                    (unaudited)

                           Three Months Ended            Nine Months Ended
                           ------------------            -----------------
                    September 26,  September 27,  September 26,  September 27,
                        2009           2008            2009           2008
                        ----           ----            ----           ----

    Cash flows from
     operating
     activities:
      Net income      $100,748       $72,766         $240,473       $199,157
      Adjustments to
       reconcile net
       income to net
       cash provided
       by operating
       activities:
        Gain on sale
         of discontinued
         operation,
         net of tax     (2,382)            -           (2,382)             -
        Depreciation
         and
         amortization   20,196        19,475           60,930         59,183
        Amortization
         of bond
         discount        1,509         1,422            4,473          4,214
        Stock-based
         compensation
         expense         6,041         6,844           18,344         23,060
        Provision for
         losses on
         trade and other
         accounts
         receivable      1,042         1,107            2,754          3,711
        Provision for
         (benefit from)
         deferred income
         taxes         (23,712)        1,137          (29,633)        (2,705)
        Stock issued
         to 401(k) plan  5,301         4,662            5,301          4,662
        Undistributed
         earnings of
         affiliates     (1,200)       (1,602)          (3,777)        (4,020)
        Other            1,044          (815)           2,535         (2,132)
        Changes in
         operating
         assets and
         liabilities,
         net of
         acquisitions:
           Accounts
            receivable (27,231)      (59,999)         (12,788)       (66,751)
           Inventories (23,482)      (63,118)         (10,234)       (68,182)
           Other current
            assets      (3,276)      (14,438)            (806)        (3,460)
           Accounts
            payable and
            accrued
            expenses    84,204        82,539          (56,813)        41,927
                        ------        ------          -------         ------
    Net cash provided
     by operating
     activities        138,802        49,980          218,377        188,664
                       -------        ------          -------        -------

    Cash flows from
     investing
     activities:
      Purchases of
       fixed assets    (10,014)      (14,653)         (38,417)       (38,119)
      Payments for
       equity
       investment and
       business
       acquisitions,
       net of cash
       acquired        (71,422)       (2,349)         (97,911)       (25,930)
      Cash received
       from business
       divestitures     12,716             -           12,716              -
      Purchases of
       available-for-
       sale securities       -             -                -        (35,925)
      Proceeds from
       sales of
       available-for-
       sale securities   4,690           725            8,730          1,572
      Net proceeds from
       foreign exchange
       forward contract
       settlements           -        14,142              275          9,090
      Other             (8,578)         (897)         (11,258)         3,607
                        ------          ----          -------          -----
    Net cash used in
     investing
     activities        (72,608)       (3,032)        (125,865)       (85,705)
                       -------        ------         --------        -------

    Cash flows from
     financing
     activities:
      Proceeds from
       (repayments of)
       bank borrowings    (436)          722           (3,829)        (5,786)
      Principal payments
       for long-term
       debt           (150,840)      (24,190)        (153,452)       (30,139)
      Proceeds from
       issuance of
       stock upon
       exercise of
       stock options     5,761        12,346            9,689         25,041
      Payments for
       repurchases of
       common stock          -       (23,298)               -        (54,945)
      Excess tax
       benefits related
       to stock-based
       compensation      2,138         5,962            2,821         10,635
      Other               (379)         (455)          (2,127)        (1,856)
                          ----          ----           ------         ------
    Net cash used in
     financing
     activities       (143,756)      (28,913)        (146,898)       (57,050)
                      --------       -------         --------        -------

    Net change in
     cash and cash
     equivalents       (77,562)       18,035          (54,386)        45,909
    Effect of exchange
     rate changes on
     cash and cash
     equivalents         1,296        (1,103)           2,423         (5,135)
    Cash and cash
     equivalents,
     beginning
     of period         393,873       271,432          369,570        247,590
                       -------       -------          -------        -------
    Cash and cash
     equivalents,
     end of period    $317,607      $288,364         $317,607       $288,364
                      ========      ========         ========       ========


    Note:  The above prior period amounts have been restated to reflect the
    adoption of ASC Topic 470-20 related to convertible debt and ASC Topic
    810-10-65 related to the presentation of noncontrolling interests.



     Exhibit A

                               Henry Schein, Inc.
                               2009 Third Quarter
                           Sales Growth Rate Summary
                                   (unaudited)


                             Q3 2009 over Q3 2008
                             --------------------

                      Consolidated  Dental  Medical  International  Technology
                      ------------  ------  -------  -------------  ----------

    Internal Sales
     Growth              -0.6%      -4.9%    -4.2%        7.0%         4.6%

    Acquisitions          4.6%       2.4%     1.1%        9.9%         2.7%
                          ---        ---      ---         ---          ---

      Local Currency
       Sales Growth       4.0%      -2.5%    -3.1%       16.9%         7.3%

     Foreign Currency
      Exchange           -3.1%      -0.5%     0.0%       -8.4%        -1.9%
                         ----       ----      ---        ----         ----

       Total Sales
         Growth           0.9%      -3.0%    -3.1%        8.5%         5.4%
                          ===       ====     ====         ===          ===

     Total Sales
      Growth excluding
      influenza vaccine
      sales               3.7%      -3.0%     8.6%        8.5%         5.4%

     Local Currency
      Sales Growth
      excluding
      influenza
      vaccine sales       6.9%      -2.5%     8.6%       16.9%         7.3%


                             Q3 YTD 2009 over Q3 YTD 2008
                             ----------------------------

                      Consolidated  Dental  Medical  International  Technology
                      ------------  ------  -------  -------------  ----------

    Internal Sales
     Growth               0.2%      -4.5%     -0.4%       5.3%         6.8%

    Acquisitions          4.7%       2.3%      1.2%      10.1%         0.9%
                          ---        ---       ---       ----          ---

      Local Currency
       Sales Growth       4.9%      -2.2%      0.8%      15.4%         7.7%

     Foreign Currency
      Exchange           -5.9%      -1.3%      0.0%     -15.0%        -3.4%
                         ----       ----       ---      -----         ----

       Total Sales
        Growth           -1.0%      -3.5%      0.8%       0.4%         4.3%
                         ====       ====       ===        ===          ===

     Total Sales
      Growth excluding
      influenza vaccine
      sales              -0.1%      -3.5%      5.1%       0.4%         4.3%

     Local Currency
      Sales Growth
      excluding
      influenza vaccine
      sales               5.9%      -2.2%      5.1%      15.4%         7.7%



        Exhibit B

                                   Henry Schein, Inc.
                               2009 Third Quarter and YTD
         Reconciliation of GAAP income from continuing operations to non-GAAP
                          income from continuing operations
                        (in thousands, except per share data)
                                      (unaudited)

                               Third Quarter     %           YTD           %
                               2009     2008  Growth    2009     2008   Growth

    Income from Continuing
     Operations attributable
     to Henry Schein, Inc.   $94,045  $67,548  39.2%  $222,143 $184,239  20.6%
    Diluted EPS from
     Continuing Operations
     attributable to Henry
     Schein, Inc.              $1.03    $0.74  39.2%     $2.45    $2.00  22.5%


    Non-GAAP Adjustments
     (after-tax)
    Foreign tax benefit     $(20,845)       -         $(20,845)       -
    Costs related to
     foreign tax benefit       1,080        -            1,080        -
    Adjustments related
     to Lehman Brothers
     Bankruptcy                 (338)  $3,045             (338)  $3,045
    Other non-recurring
     income/expense, net      (1,028)       -           (1,028)       -
    Restructuring costs            -        -            2,784        -
                                 ---      ---            -----      ---
    Total non-GAAP
     adjustments to income
     from Continuing
     Operations attributable
     to Henry Schein, Inc.  $(21,131)  $3,045         $(18,347)  $3,045
    Total non-GAAP
     adjustments to
     diluted EPS from
     Continuing Operations
     attributable to Henry
     Schein, Inc.             $(0.23)   $0.03           $(0.20)   $0.03

    Non-GAAP income from
     Continuing Operations
     attributable to Henry
     Schein, Inc.            $72,914  $70,593   3.3%  $203,796 $187,284   8.8%
    Non-GAAP diluted EPS
     from Continuing
     Operations attributable
     to Henry Schein, Inc.     $0.80    $0.77   3.9%     $2.25    $2.04  10.3%
                               -----    -----   ---      -----    -----  ----


    This non-GAAP comparison is being presented in order to provide a more
    comparable basis for analysis.  Earnings per share numbers may not sum
    due to rounding.

SOURCE Henry Schein, Inc.

Investors: Steven Paladino, Executive Vice President and Chief Financial Officer, steven.paladino@henryschein.com, +1-631-843-5500, or Media: Susan Vassallo, Vice President, Corporate Communications, susan.vassallo@henryschein.com, +1-631-843-5562